Biophytis SA represents values of innovation, collaboration, and dedication to improving patients' lives. The company's corporate philosophy revolves around developing novel therapeutics targeting age-related diseases, including sarcopenia and ophthalmic conditions. By combining cutting-edge scientific research with a patient-centered approach, Biophytis SA aims to bring transformative solutions to individuals confronted with these health challenges. With a strong focus on research and development, Biophytis SA strives to leverage its expertise and partnerships to advance breakthrough treatments, ultimately enhancing patients' well-being and quality of life.

Biophytis SA is primarily present in France, Belgium, the United States, and Switzerland.

Biophytis SA has achieved several significant milestones in its journey. The company successfully completed a Phase 2 clinical trial for its lead product candidate, Sarconeos (BIO101), in patients with sarcopenia. Biophytis SA also reached an important collaboration agreement with the global pharmaceutical company, Ipsen, to develop and commercialize Sarconeos for Duchenne Muscular Dystrophy. Furthermore, the company secured additional funding through private placements, enabling continued research and development efforts. With these accomplishments, Biophytis SA has demonstrated its commitment to advancing innovative therapeutic solutions, focusing on age-related diseases, and strengthening its position in the biopharmaceutical industry.

Biophytis SA is a French biotechnology company specializing in the development of innovative therapies for age-related diseases. Established in 2006, Biophytis focuses on researching and developing treatments for debilitating conditions such as sarcopenia and neurodegenerative disorders. The company's mission is to improve the quality of life for the elderly by developing drugs that target the biological mechanisms associated with aging. With a strong emphasis on scientific research and collaboration with renowned academic institutions, Biophytis has made significant strides in advancing its therapeutic pipeline. Through its commitment to innovation and aging-related diseases, Biophytis SA continues to drive advancements in biotechnology.

The main competitors of Biophytis SA in the market include companies such as Novartis AG, Pfizer Inc., Genentech (a member of the Roche Group), and Amgen Inc.

Biophytis SA is primarily active in the field of biotechnology and healthcare.

The business model of Biophytis SA centers around the development and commercialization of innovative therapeutics to address age-related diseases, with a particular focus on muscle-related disorders. Biophytis SA aims to uncover the potential of natural compounds and proprietary drug candidates to improve patients' health and quality of life. The company conducts extensive research in the field of molecular mechanisms and physiology to identify promising drug targets. By leveraging its expertise in preclinical and clinical development, Biophytis SA strives to bring safe and effective treatments to market, addressing unmet needs in geriatric conditions.

KGV kan for øyeblikket ikke beregnes for Biophytis.

KUV kan for øyeblikket ikke beregnes for Biophytis.

AlleAktien kvalitetsscore for Biophytis er 5/10.

Omsetningen kan for øyeblikket ikke beregnes for Biophytis.

Resultatet kan for øyeblikket ikke beregnes for Biophytis.

The French biopharmaceutical company Biophytis SA has been listed on Euronext Paris since 2006 and is dedicated to researching and developing innovative therapies for the treatment of age-related diseases and other conditions. The company focuses on two areas: sarcopenia and neurodegenerative diseases. Sarcopenia refers to age-related muscle loss, which is associated with an increased risk of falls, fractures, and disabilities. Biophytis aims to combat this disease through the development of drugs and therapies. The company is currently working on a medication called Sarconeos, which stimulates muscle growth and aims to slow the progression of sarcopenia. Biophytis has already achieved positive results in Phase 2 clinical trials and plans to expand the clinical studies into Phase III. The company is also working on therapies for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. In this area, Biophytis has launched the Macuneos project, which aims to develop treatments for age-related macular degeneration (AMD). AMD is an eye disease that occurs with advancing age and can lead to irreversible vision loss. Macuneos is based on a technology that relies on carotenoids and aims to slow down the degeneration of retinal cells through its antioxidant effect. Biophytis has already published positive results in early clinical studies and plans to conduct further studies. Biophytis' business strategy is to work in partnerships with other pharmaceutical companies to advance the development and commercialization of their therapies. Biophytis has already formed partnerships with leading pharmaceutical companies such as Ipsen and Serum Institute of India. In addition to the aforementioned therapy areas, Biophytis is also working on other projects, including BPN14770, a potential medication for the treatment of Fragile X syndrome, a genetic disorder that can cause intellectual disabilities and autism. Additionally, Biophytis has announced plans to collaborate with NASA on a project to combat muscle wasting in astronauts. In summary, Biophytis is an emerging biopharmaceutical company that focuses on the development of therapies to combat age-related diseases and neurodegenerative conditions. The company works closely with other pharmaceutical companies to advance its research and development and has already achieved positive results in early clinical studies. With its wide range of ongoing projects and promising partnerships, Biophytis has the potential to become a key player in the biopharmaceutical market.

Biophytis utbetaler et dividende på 0 EUR fordelt over utdelinger i året.

Utbyttet kan for øyeblikket ikke beregnes for Biophytis eller så utdeler ikke selskapet utbytte.

ISIN-en til Biophytis er FR0012816825.

WKN for Biophytis er A14V4J.

Tikkeren til Biophytis er ALBPS.PA.

I løpet av de siste 12 månedene utbetalte Biophytis et utbytte på . Dette tilsvarer en utbytteavkastning på ca. . For de neste 12 månedene vil Biophytis sannsynligvis betale et utbytte på 0 EUR.

Utdelingsrendementet til Biophytis er for øyeblikket .

Biophytis betaler utbytte kvartalsvis. Dette blir utdelt i månedene .

Biophytis betalte utbytte hvert år de siste 0 årene.

For de kommende 12 månedene forventes det utbytter på 0 EUR. Dette tilsvarer en utbytteavkastning på 0 %.

Biophytis tilordnes sektoren 'Helse'.

For å motta den siste utbyttet fra Biophytis den på 0 EUR, måtte du ha aksjen i porteføljen din før ex-datoen den .

Utbetalingen av det siste utbyttet fant sted den .

I løpet av 2023 ble det utbetalt 0 EUR i utbytte fra Biophytis.

Utdelingene fra Biophytis blir betalt ut i EUR.